State Street’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-5,143,739
| Closed | -$31M | – | 3834 |
|
|
2019
Q4 | $31M | Buy |
5,143,739
+642,125
| +14% | +$3.72M | ﹤0.01% | 1837 |
|
|
2019
Q3 | $16.2M | Sell |
4,501,614
-1,172,149
| -21% | -$4.52M | ﹤0.01% | 2191 |
|
|
2019
Q2 | $15.2M | Sell |
5,673,763
-521,259
| -8% | -$1.54M | ﹤0.01% | 2278 |
|
|
2019
Q1 | $18.3M | Buy |
6,195,022
+1,221,045
| +25% | +$3M | ﹤0.01% | 2101 |
|
|
2018
Q4 | $7.91M | Buy |
4,973,977
+160,408
| +3% | +$453K | ﹤0.01% | 2533 |
|
|
2018
Q3 | $17.7M | Sell |
4,813,569
-1,213,670
| -20% | -$3.62M | ﹤0.01% | 2257 |
|
|
2018
Q2 | $17.1M | Buy |
6,027,239
+109,374
| +2% | +$373K | ﹤0.01% | 2235 |
|
|
2018
Q1 | $22M | Buy |
5,917,865
+202,991
| +4% | +$664K | ﹤0.01% | 1992 |
|
|
2017
Q4 | $16.5M | Buy |
5,714,874
+1,354,991
| +31% | +$4.92M | ﹤0.01% | 2182 |
|
|
2017
Q3 | $19.6M | Buy |
4,359,883
+385,454
| +10% | +$1.71M | ﹤0.01% | 2046 |
|
|
2017
Q2 | $18.2M | Sell |
3,974,429
-342,787
| -8% | -$1.38M | ﹤0.01% | 2046 |
|
|
2017
Q1 | $18.2M | Sell |
4,317,216
-803,944
| -16% | -$3.34M | ﹤0.01% | 2017 |
|
|
2016
Q4 | $21.2M | Buy |
5,121,160
+1,465,723
| +40% | +$7.79M | ﹤0.01% | 1853 |
|
|
2016
Q3 | $29.6M | Buy |
3,655,437
+646,882
| +22% | +$5.5M | ﹤0.01% | 1509 |
|
|
2016
Q2 | $23.5M | Sell |
3,008,555
-719,112
| -19% | -$6.17M | ﹤0.01% | 1643 |
|
|
2016
Q1 | $28.8M | Sell |
3,727,667
-416,344
| -10% | -$3.05M | ﹤0.01% | 1475 |
|
|
2015
Q4 | $44.7M | Sell |
4,144,011
-856,518
| -17% | -$7.79M | ﹤0.01% | 1231 |
|
|
2015
Q3 | $34.6M | Buy |
5,000,529
+25,026
| +0.5% | +$204K | ﹤0.01% | 1377 |
|
|
2015
Q2 | $44.1M | Buy |
4,975,503
+1,217,690
| +32% | +$11.5M | ﹤0.01% | 1346 |
|
|
2015
Q1 | $37.1M | Buy |
3,757,813
+918,910
| +32% | +$11.5M | ﹤0.01% | 1411 |
|
|
2014
Q4 | $34.8M | Buy |
2,838,903
+31,154
| +1% | +$380K | ﹤0.01% | 1420 |
|
|
2014
Q3 | $28M | Buy |
2,807,749
+1,245,222
| +80% | +$11.6M | ﹤0.01% | 1498 |
|
|
2014
Q2 | $11.8M | Sell |
1,562,527
-5,322,902
| -77% | -$21.2M | ﹤0.01% | 2151 |
|
|
2014
Q1 | $22.7M | Buy |
6,885,429
+724,557
| +12% | +$2.54M | ﹤0.01% | 1686 |
|
|
2013
Q4 | $20.5M | Buy |
6,160,872
+1,968,372
| +47% | +$5.71M | ﹤0.01% | 1729 |
|
|
2013
Q3 | $12.7M | Buy |
4,192,500
+883,143
| +27% | +$6.05M | ﹤0.01% | 1997 |
|
|
2013
Q2 | $27.1M | Buy |
+3,309,357
| New | +$25.3M | ﹤0.01% | 1451 |
|
State Street's ACHN Position: Q1 2020 in Review
State Street sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 5,143,739 shares — an estimated $31M sold.
State Street first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $44.7M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- State Street reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- State Street sold 5,143,739 Achillion Pharmaceuticals shares in Q1 2020, an estimated $31M.
- State Street first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- State Street's Achillion Pharmaceuticals position peaked at $44.7M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on State Street's 13F filing for Q1 2020, filed 11 May 2020.